title: Islet transplantation for brittle type 1 diabetes: the UIC protocol.
abstract: This prospective phase 1/2 trial investigated the safety and reproducibility of allogeneic islet transplantation (Tx) in type I diabetic (T1DM) patients and tested a strategy to achieve insulin-independence with lower islet mass. Ten C-peptide negative T1DM subjects with hypoglycemic unawareness received 1-3 intraportal allogeneic islet Tx and were followed for 15 months. Four subjects (Group 1) received the Edmonton immunosuppression regimen (daclizumab, sirolimus, tacrolimus). Six subjects (Group 2) received the University of Illinois protocol (etanercept, exenatide and the Edmonton regimen). All subjects became insulin- independent. Group 1 received a mean total number of islets (EIN) of 1460 080 +/- 418 330 in 2 (n = 2) or 3 (n = 2) Tx, whereas Group 2 became insulin- independent after 1 Tx (537 495 +/- 190 968 EIN, p = 0.028). All Group 1 subjects remained insulin free through the follow-up. Two Group 2 subjects resumed insulin: one after immunosuppression reduction during an infectious complication, the other with exenatide intolerance. HbA1c reached normal range in both groups (6.5 +/- 0.6 at baseline to 5.6 +/- 0.5 after 2-3 Tx in Group 1 vs. 7.8 +/- 1.1 to 5.8 +/- 0.3 after 1 Tx in Group 2). HYPO scores markedly decreased in both groups. Combined treatment of etanercept and exenatide improves islet graft function and facilitates achievement of insulin-independence with less islets.
authors.affiliation: Division of Transplantation/Department of Surgery, University of Illinois at Chicago, Chicago, IL, USA.
authors.forename: A
authors.initials: A
authors.lastname: Gangemi
authors.forename: P
authors.initials: P
authors.lastname: Salehi
authors.forename: B
authors.initials: B
authors.lastname: Hatipoglu
authors.forename: J
authors.initials: J
authors.lastname: Martellotto
authors.forename: B
authors.initials: B
authors.lastname: Barbaro
authors.forename: J B
authors.initials: JB
authors.lastname: Kuechle
authors.forename: M
authors.initials: M
authors.lastname: Qi
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
authors.forename: P
authors.initials: P
authors.lastname: Pallan
authors.forename: C
authors.initials: C
authors.lastname: Owens
authors.forename: J
authors.initials: J
authors.lastname: Bui
authors.forename: D
authors.initials: D
authors.lastname: West
authors.forename: B
authors.initials: B
authors.lastname: Kaplan
authors.forename: E
authors.initials: E
authors.lastname: Benedetti
authors.forename: J
authors.initials: J
authors.lastname: Oberholzer
mesh_terms: D002985:Clinical Protocols; D003922:Diabetes Mellitus, Type 1 / Q000601:surgery*; D000068800:Etanercept; D000077270:Exenatide; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016381:Islets of Langerhans Transplantation; D010455:Peptides / Q000627:therapeutic use; D011446:Prospective Studies; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D014688:Venoms / Q000627:therapeutic use
chemical_list: D007004:Hypoglycemic Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D010455:Peptides; D018124:Receptors, Tumor Necrosis Factor; D014688:Venoms; D000077270:Exenatide; D000068800:Etanercept